VRS.L

Versarien Plc
Versarien PLC - Distribution Agreement for Graphene Biosensors
9th December 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2320P
Versarien PLC
09 December 2024
 

Reach - Non-Regulatory

9 December 2024

Versarien Plc

("Versarien" or the "Company")

Distribution Agreement for Graphene Biosensors

Versarien Plc (AIM: VRS), the advanced engineering materials group, is pleased to announce the launch of a new biosensor chip utilising novel graphene barristor sensor platform technology.  These graphene barristor devices, developed in South Korea by A Barristor Company ("ABC"), will utilise chemical vapour deposition ("CVD") grown graphene, that is produced under a Versarien licence.  Versarien has signed a distribution agreement with ABC to distribute the products in the UK and Europe.

A barristor (triode device) is a new type of graphene-based transistor with a Schottky barrier between graphene and silicon.  The current modulation is amplified more than 10,000 times compared to graphene field-effect transistors ("GFET") enabling the barristor transistors to overcome many GFET limitations.  In these new products, the graphene surface is terminated with either pyrenebutanoic acid succinimidyl ester ("PBASE") or a customer preferred linker.  PBASE is one of the most frequently used linkers for the surface modification of field-effect transistor (FET) biosensors based on carbon nanotubes and graphene.  The products can be supplied as individual chips or on a wafer scale.

It is expected that the CVD graphene used in the products will be supplied by MCK Tech Co. Ltd. ("MCK Tech") in South Korea, which is an existing licencing partner of Versarien, and it will also undertake some of the device fabrication.

The range of sensor products to be distributed by Versarien may be expanded at a later date based on ABC's product developments, such as in infrared detection, gas/chemical detection, temperature detection or multiple sensor on a chip technology.

Commenting, Dr Stephen Hodge, Versarien CEO, stated: "I am delighted that we have signed this distribution agreement with ABC to market their innovative graphene based biosensors in the UK and Europe.  I had the privilege of collaborating with ABC's CEO, Prof. Hyun-Jong Chung, for several years prior to joining Versarien.  It is exciting to see this sensor platform come to fruition and I anticipate it will drive significant advancements in medical diagnostics.  This agreement will allow Versarien to further benefit from the IP licenced to MCK Tech and we look forward to continuing to work with ABC both regarding the newly launched biosensors and as they expand their sensor capabilities."

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

 

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

 

+44 (0)20 3470 0470

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

For further information please see: http://www.versarien.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAFAXEAKLFFA]]>
TwitterFacebookLinkedIn